The case for & against
Bull & Bear analysis
Bearish
Milestone Scientific Inc. (NYSE: MLSS) specializes in developing innovative medical technologies, primarily focused on its CompuFlow systems for dental and medical applications. The company has recently pivoted to a direct sales model, enhancing its market reach and operational efficiency. Positioned within the growing healthcare technology sector, Milestone aims to capitalize on advancements in pain management and procedural accuracy, striving for increased adoption of its products while tapping into both domestic and international markets.
Bull says
- ↑Revenue up 25% YoY to $2.3M in Q2’25, led by dental segment
- ↑CompuFlow system targets $400M market at 20% penetration
- ↑Operating loss narrowed to $1.1M in Q4’25 from $2M YoY
- ↑Gross margin rose to ~70%, reflecting high-margin sales strategy
- ↑E-commerce sales climbed 31% in Q1’24 after direct-sales pivot
- ↑Analysts upgrading earnings outlook amid low leverage and strong profitability
Bear says
- ↓International revenue fell to ~$930K in Q1’24, limiting diversification
- ↓$5.7M operating loss in 2025 underscores sustained unprofitability
- ↓Complex Medicare reimbursement process may delay CompuFlow sales
- ↓High short interest signals market skepticism on stock prospects
- ↓Small size and weak momentum elevate volatility risk
- ↓Direct-sales model remains unproven beyond ten active clinics
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 07-15-2026neutral
Transcript signals
Bull points
- The U.S. e-commerce revenue for the three months ended March 31, 2024 was approximately $1.3 million compared to $989,000 at March 31, 2023, indicating strong growth in our new sales channel.
- The increase in gross profit margin was due to higher margin sales with the launch of the new online store.
- Most notably, e-commerce sales, which reflect our new online sales portal, achieved growth of 31% over the same period last year.
Bear points
- Thank you, Arjun. For the quarter ending March 31, 2024 and 2023, revenue was approximately $2.2 million and $2.6 million, respectively.
- Operating losses for the three months ending March 31st, 2024 was approximately $1.5 million versus $1.3 million for the first quarter ending March 31st, 2023. Net loss was approximately $1.4 million or $2.5 cents per share for the three months ending March 31st, 2024 versus net loss of 1.3 million or two cents per share for the comparable period in 2023.
- Although our revenue was down slightly compared to the same period last year, this was largely a reflection of a reserve reversal in the first quarter of 2023, coupled with a decline in international sales during the first quarter of 2024.
Read full transcript analysis ›